GC Biopharma Corp.
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 006280.KS | 195940.KQ | IPCALAB.NS | 0QFP.IL | GRANULES.BO | MOREPENLAB.NS | |
|---|---|---|---|---|---|---|
| Market cap | 1.62T | 1.04T | 494.62B | 4.46T | 192.80B | 53.21B |
| P/E (TTM) | — | — | 37.8 | 18.8 | 35.3 | 28.3 |
| Forward P/E | — | — | 27.7 | — | 26.5 | — |
| Price/book | — | — | 6.1 | 2.1 | 4.8 | 3.9 |
| Dividend yield | 1.08% | 1.20% | 0.30% | 7.74% | 0.26% | 0.20% |
| 1-year change | +5.32% | −30.39% | +51.13% | 0.00% | +0.63% | +113.46% |
| Today | +2.67% | +7.01% | −1.14% | +156.25% | −0.01% | −4.17% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 20 min.
Latest news
All 006280.KS news ›[Click e-Stock] GC Biopharma's Global Drug Pipeline Value in Focus... Target Price Raised
Published 03 Nov.2026 07:22(KST) Samsung Securities maintained its “Buy (BUY)” rating on GC Biopharma on November 3, citing expanding U.S. sales of its blood product Aliglo and the establishment of a mid- to long-term growth driver through…
GC Biopharma, Hanmi License Fabry Drug to BioMarin in $475M Deal
Next-Generation Fabry Disease Treatment: $70 Million Upfront, Up to $405 Million in Milestones Long-Acting Therapy Designed for Subcutaneous Injection Instead of Intravenous Infusion Global Phase 1/2 Trials Under Way; Korean Approval and…
More from 1 other outlet
BioMarin Licenses Fabry Disease Therapy From GC Biopharma and Hanmi
The license grants BioMarin worldwide rights to the candidate excluding Korea, where GC Biopharma and Hanmi retain commercialization rights for HM15421/GC1134A. Following the ongoing Phase 1/2 study, BioMarin will assume sole…
GC Biopharma wins Korea’s first OK for intraventricular Hunterase ICV
GCGC Biopharma(006280) has received Korea's first approval for a treatment for Hunter syndrome patients with central nervous system symptoms. GC Biopharma said on the 30th that its intraventricular Hunter syndrome treatment "Hunterase ICV…
BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry Disease
Oct 29, 2026, 08:45 ET BioMarin will make an upfront payment of $70 million; GC and Hanmi will be jointly eligible to receive additional payments upon certain development and commercial milestones, and tiered royalties on net sales of…
IBK Securities lifts GC Biopharma outlook as profit rises despite softer Q3 sales
CHOSUNBIZ Chosunbiz IBK Securities lifts GC Biopharma outlook as profit rises despite softer Q3 sales IBK Securities said on the 21st that although revenue for GC Biopharma(006280) will likely decline in the third q
GC Biopharma Sees Operating Profit Surge Despite Sales Decline
IBK Securities cites high-margin products, reduced losses; maintains Buy rating, 190,000 won target
GC Biopharma, LG CNS team up to automate vaccine, drug manufacturing
GC Biopharma has partnered with LG CNS to introduce AI-based automation across its pharmaceutical manufacturing facilities, targeting production, quality control and logistics under a modernization plan extending through 2030. The Korean…
GC Biopharma and LG CNS build AI smart factories across South Korea
GC Biopharma(006280) said on the 14th that it will build a smart factory with LG CNS. It will automate production processes with artificial intelligence (AI) through 2030 and strengthen quality control. The Ochang plant in North…
GC Biopharma to Present Expanded IVIG Aggregation Analysis and Additional Phase 3 ALYGLO® Safety Analysis at IgNS 2026
New analyses include a multi-lot comparison of commercially available 10% IVIG products and additional characterization of selected safety outcomes from the Phase 3 ALYGLO® study GC Biopharma will also host a patient advocacy symposium…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- biz.chosun.com3
- en.sedaily.com3
- asiae.co.kr1
- biospace.com1
- chosun.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 13 articles, not a forecast.